Lunit announced that 11 abstracts featuring its artificial intelligence (AI)-biomarker platform will be presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting to be held June 3-7 in Chicago.
Seven poster presentations and four online publications, including research on AI biomarkers, have been accepted by ASCO, with findings demonstrating the practical use of Lunit's AI software in the pathological assessment of cancer, the company said.
Highlights include one study focused on the use of Lunit's AI technology to define tumor immune phenotypes. Findings from the study validate the effectiveness of Lunit SCOPE IO in predicting clinical outcomes for immunotherapy across more than 16 different cancer types, the company said.
In another presentation, researchers assessed the practical efficacy of Lunit SCOPE PD-L1, an AI-powered PD-L1 tumor proportion score (TPS) analyzer, which recently received the CE mark in Europe.
The company's four abstracts include a study evaluating the performance of Lunit SCOPE HER2 in reducing interobserver variation among pathologists and a study of the landscape of tumor-infiltrating lymphocytes (TIL) in neuroendocrine tumors using the Lunit SCOPE IO.